ClinVar Miner

Submissions for variant NM_007294.4(BRCA1):c.2210_2211del (p.Thr737fs)

dbSNP: rs80357654
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 10
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) RCV000031037 SCV000299721 pathogenic Breast-ovarian cancer, familial, susceptibility to, 1 2016-09-08 reviewed by expert panel curation Variant allele predicted to encode a truncated non-functional protein.
Labcorp Genetics (formerly Invitae), Labcorp RCV000047759 SCV000075772 pathogenic Hereditary breast ovarian cancer syndrome 2023-04-06 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Thr737Serfs*2) in the BRCA1 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in BRCA1 are known to be pathogenic (PMID: 20104584). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with breast and ovarian cancer (PMID: 9667259). This variant is also known as 2329delCA. ClinVar contains an entry for this variant (Variation ID: 37456). For these reasons, this variant has been classified as Pathogenic.
Ambry Genetics RCV000131875 SCV000186930 pathogenic Hereditary cancer-predisposing syndrome 2023-11-16 criteria provided, single submitter clinical testing The c.2210_2211delCA pathogenic mutation, located in coding exon 9 of the BRCA1 gene, results from a deletion of two nucleotides at nucleotide positions 2210 to 2211, causing a translational frameshift with a predicted alternate stop codon (p.T737Sfs*2). This alteration was identified in a female diagnosed with bilateral breast cancer and ovarian cancer (Frank TS et al. J. Clin. Oncol. 1998; 16:2417-25). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation.
GeneDx RCV000236097 SCV000293471 pathogenic not provided 2018-02-21 criteria provided, single submitter clinical testing This deletion of 2 nucleotides in BRCA1 is denoted c.2210_2211delCA at the cDNA level and p.Thr737SerfsX2(T737SfsX2) at the protein level. The normal sequence, with the bases that are deleted in braces, is GAAA[CA]GTTA. The deletion causes a frameshift, which changes a Threonine to a Serine at codon 737, and creates a premature stop codon at position 2 of the new reading frame. This variant is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. BRCA1 c.2210_2211delCA, published as c.2329delCA using alternate nomenclature, was observed in a patient with ovarian and bilateral breast cancer (Frank 1998). We consider this variant to be pathogenic.
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), c/o University of Cambridge RCV000031037 SCV000325290 pathogenic Breast-ovarian cancer, familial, susceptibility to, 1 2015-10-02 criteria provided, single submitter clinical testing
All of Us Research Program, National Institutes of Health RCV000031037 SCV004839385 pathogenic Breast-ovarian cancer, familial, susceptibility to, 1 2023-12-07 criteria provided, single submitter clinical testing The c.2210_2211del (p.Thr737Serfs*2) variant of the BRCA1 gene creates an early stop codon. It is expected to result in an absent or disrupted protein product. This variant has been reported in an individual with breast and ovarian cancer (PMID: 9667259). ClinVar contains an entry for this variant (ID: 37456). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Truncating variants in BRCA1 gene are known to be pathogenic (PMID: 21989022, 17661172, 22762150). Therefore the c.2210_2211del (p.Thr737Serfs*2) variant of the BRCA1 gene is classified as pathogenic.
Sharing Clinical Reports Project (SCRP) RCV000031037 SCV000053631 pathogenic Breast-ovarian cancer, familial, susceptibility to, 1 2012-05-08 no assertion criteria provided clinical testing
Breast Cancer Information Core (BIC) (BRCA1) RCV000031037 SCV000144337 pathogenic Breast-ovarian cancer, familial, susceptibility to, 1 1997-11-14 no assertion criteria provided clinical testing
Research Molecular Genetics Laboratory, Women's College Hospital, University of Toronto RCV000047759 SCV000587199 pathogenic Hereditary breast ovarian cancer syndrome 2014-01-31 no assertion criteria provided research
BRCAlab, Lund University RCV000031037 SCV004244098 pathogenic Breast-ovarian cancer, familial, susceptibility to, 1 2020-03-02 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.